

Cover Story
By Matthew Bin Han Ong
In the next few weeks, FDA will announce its decision on Novartis's Zarxio, a granulocyte-colony stimulating factor biosimilar to Amgen's Neupogen.
By Matthew Bin Han Ong
By Matthew Bin Han Ong
In Brief
Funding Opportunities
Drugs & Targets
Trending Stories
- DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - In her own words: Rathmell reflects on her priorities and values—and encourages everyone to do the same
- Steven Libutti tells us about building a $900 million cancer hospital for Rutgers RWJBarnabas Health
- Makary vows to speed up drug approvals and end FDA’s “cozy” relationship with industry
Commissioner promises to protect scientific integrity while bringing in “fresh” MAHA ideas - Ci4CC’s 23rd Cancer Center Summit to focus on accelerating oncology innovation through AI
- White House preliminary budget document provides no funds for highly impactful CDC cancer registries program